Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN11 | Q06124 | 20/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21154462 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL21154418 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL30295961 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL29478950 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL29374178 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL25094875 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL21154556 | 1.00 | PTPN11 (1.00) | PTPN11KCNH2EGFR | |
| SCHEMBL20807077 | 0.93 | PTPN11 (0.87) | PTPN11KCNH2EGFR | |
| SCHEMBL24233670 | 0.91 | PTPN11 (0.84) | PTPN11KCNH2EGFR | |
| SCHEMBL20807079 | 0.91 | PTPN11 (0.83) | PTPN11KCNH2EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240423984-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SHP-2 INHIBITORS | MIRATI THERAPEUTICS, INC | 2024-12-26 | — | — | US | claimed |
| US-20220079947-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. | 2022-03-17 | — | — | US | claimed |
| EP-3890716-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | claimed |
| WO-2020118066-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-06-11 | — | — | WO | claimed |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-12570672-B2 | Macrocyclic compounds and methods of use | AMGEN INC. | 2026-03-10 | — | — | US | disclosed |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4313981-B1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER (US) | 2026-02-25 | — | — | EP | disclosed |
| US-20250352490-A1 | P-SELECTIN TARGETED NANOPARTICLES AND USES THEREOF | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2025-11-20 | — | — | US | disclosed |
| EP-4351582-B1 | COMBINATION OF A PARTICULAR BRAF INHIBITOR (PARADOX BREAKER) AND A PD-1 AXIS BINDING ANTAGONIST FOR USE IN THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2025-10-08 | — | — | EP | disclosed |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | PFIZER INC. (US) | 2025-08-21 | — | — | US | disclosed |
| US-12377101-B2 | Combination therapies | Mirati Therapeutics, Inc. (US) | 2025-08-05 | — | — | US | disclosed |
| WO-2020118066-A1 | COMBINATION THERAPIES | Mirati Therapeutics, Inc. (US) | 2020-06-11 | — | — | WO | disclosed |
| US-10590090-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2019-07-11 | — | — | US | disclosed |
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2019-07-11 | — | — | US | disclosed |
| EP-3484856-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2019-05-22 | — | — | EP | disclosed |
| WO-2019051084-A1 | SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER | Revolution Medicines, Inc. (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-2018013597-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
| WO-2018013597-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | Revolution Medicines, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423984-A1 | COMBINATION THERAPIES OF KRAS G12D INHIBITORS WITH SHP-2 INHIBITORS | KRAS, NRAS, SHPRH | PTPN11 24/4885KCNH2 4609/4885EGFR 126/4885 |
| US-10590090-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN22, PTPN2 | PTPN11 8/4885KCNH2 2485/4885EGFR 2069/4885 |
| US-20250352490-A1 | P-SELECTIN TARGETED NANOPARTICLES AND USES THEREOF | SELP, SELPLG, SELL | PTPN11 606/4885KCNH2 4852/4885EGFR 2472/4885 |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | PTPN11 663/4885KCNH2 1627/4885EGFR 59/4885 |
| US-20190210977-A1 | 2,5-DISUBSTITUTED 3-METHYL PYRAZINES AND 2,5,6-TRISUBSTITUTED 3-METHYL PYRAZINES AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN2, PTPN22 | PTPN11 12/4885KCNH2 3436/4885EGFR 980/4885 |
| US-12570672-B2 | Macrocyclic compounds and methods of use | KRAS, NRAS, BRAF | PTPN11 152/4885KCNH2 2164/4885EGFR 419/4885 |
| US-20220079947-A1 | COMBINATION THERAPIES | KRAS, NRAS, HRAS | PTPN11 9/4885KCNH2 4389/4885EGFR 234/4885 |
| US-20250263411-A1 | 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS | NRAS, KRAS, BRAF | PTPN11 1363/4885KCNH2 2874/4885EGFR 305/4885 |
| US-12377101-B2 | Combination therapies | KRAS, NRAS, HRAS | PTPN11 9/4885KCNH2 4389/4885EGFR 234/4885 |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN6, PTPN2 | PTPN11 6/4885KCNH2 1681/4885EGFR 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.